Cancer
Conditions
Brief summary
This study will test the acceptability and feasibility of a telehealth intervention to improve communication between patients and medical providers in adolescent and young adult (AYA) cancer patients receiving chemotherapy treatment.
Interventions
BEHAVIORALTelehealth visits
Receiving telehealth visits with a medical provider (MD or NP) 2-3 days after last chemotherapy administration in the cycle
BEHAVIORALStandard of Care
Receiving care as usual from the UC Davis Comprehensive Cancer Center
Sponsors
University of California, Davis
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
2 telehealth visits with a medical provider (either an MD or NP) after last chemotherapy administration in the cycle, or as otherwise indicated
Eligibility
Sex/Gender
ALL
Age
12 Years to 29 Years
Healthy volunteers
No
Inclusion criteria
* Patients with cancer undergoing active treatment and who have received at least two cycles of chemotherapy * Access to Epic MyChart (we will facilitate access to MyChart for interested patients who are not yet signed up) * Access to a smartphone or tablet to access EPIC MyChart telehealth appointments
Exclusion criteria
* Non-English or non-Spanish speaking patients * Potentially completing therapy during study period (including follow-up period) or plans to leave UCDCCC during study period
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of Patients Completing the Trial | end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days) | \>65% of enrolled patients will complete the trial |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Survey Response Rate | end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days) | \>%70% of enrolled patients will complete the survey instruments |
| Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ) | end of the study period (6 cycles of chemotherapy for each participant, where each cycle is 14-28 days) | A composite score of ≥40 (based on 10 items with a Likert scale of 1-5 strongly disagree to strongly agree) |
Countries
United States
Outcome results
None listed